In our study, we highlighted significant reductions of CRP, ESR, TNF-α, and IL-6 after 9 weeks of EVOO administration, confirming the cardioprotective action of EVOO with a very high MPC content in CKD patients. The gene discussed is ESR1; the disease is chronic kidney disease.